Tarsus Pharmaceuticals, Inc.
Develops novel therapies for eye care, including the first FDA-approved Demodex blepharitis drug.
TARS | US
Overview
Corporate Details
- ISIN(s):
- US87650L1035
- LEI:
- Country:
- United States of America
- Address:
- 15440 LAGUNA CANYON ROAD, 92618 IRVINE
- Website:
- https://www.tarsusrx.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for diseases with limited treatment options. The company's primary focus begins with eye care, applying proven science and new technology to address unmet patient needs. Its flagship product, XDEMVY® (lotilaner ophthalmic solution), is the first and only FDA-approved treatment for Demodex blepharitis. Tarsus is also advancing a robust pipeline of therapeutic candidates for other prevalent conditions, including potential treatments for rosacea and a preventative therapy for Lyme disease.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Tarsus Pharmaceuticals, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Tarsus Pharmaceuticals, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Tarsus Pharmaceuticals, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
